Influence of Concurrent Mutations on Overall Survival in EGFR-mutated Non-small Cell Lung Cancer.

ABSTRACT:

Background/aim

Non-small cell lung cancer (NSCLC) patients with activating somatic mutations in the epidermal growth factor receptor (EGFR) have better outcomes with tyrosine kinase inhibitors (TKIs) than with chemotherapy. However, even with the most effective therapies, not all patients respond. The presence of concurrent pathogenic mutations could play a role in resistance. The objective of this study was to analyze the impact of concurrent mutations in genes other than EGFR on survival outcomes of patients treated with TKIs for EGFR-mutated NSCLC.

Patients and methods

We conducted a retrospective cohort analysis of patients with advanced NSCLC treated with TKIs in our center between January 2016 and December 2019. Clinical and pathological characteristics, EGFR mutationa

SUBMITTER: Chevallier M 

PROVIDER: S-EPMC7472449 | biostudies-literature | 2020 Sep-Oct

REPOSITORIES: biostudies-literature